Milsaperidone (VHX-896) vs Risperidone (Uzedy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Uzedy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT03503318 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).

Reported efficacy

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)

Result source: NCT03503318

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Risperidone (Uzedy)
PANSS total, change—Not reported—Not posted · NCT00159770
CGI-S, change—Not reported—Not posted · NCT00159770
PANSS response—Not reported—Not posted · NCT00159770
PSP, change—Not reported—Not posted · NCT00159770
Relapse (% of patients)—Not reported7.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Uzedy)
—Not posted · NCT00159770

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Uzedy)
—Not posted · NCT00159770

PANSS response

Milsaperidone (VHX-896)
—Not reported
Risperidone (Uzedy)
—Not posted · NCT00159770

PSP, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Uzedy)
—Not posted · NCT00159770

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Risperidone (Uzedy)
7.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRisperidone (Uzedy)
Dropout rate
21.3%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
22.2%q2m
NCT03503318 · Phase 3 · monotherapy
22.4%q1m
NCT03893825 · Phase 3 · monotherapy
24.7%q2m
NCT03893825 · Phase 3 · monotherapy
Discontinued due to AEs
2.2%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
1.1%q2m
NCT03503318 · Phase 3 · monotherapy
0%q1m
NCT03893825 · Phase 3 · monotherapy
1.2%q2m
NCT03893825 · Phase 3 · monotherapy
Serious AEs
4.4%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
5.6%q2m
NCT03503318 · Phase 3 · monotherapy
4.7%q1m
NCT03893825 · Phase 3 · monotherapy
6.8%q2m
NCT03893825 · Phase 3 · monotherapy
Most frequent reported AEs
q1ma
injection site nodule 6.6% (placebo 3.4%)
insomnia 6.6% (placebo 5.6%)
injection site pruritus 5.5% (placebo 2.2%)
NCT03503318 · Phase 3 · monotherapy
show 3 more results
q2m
injection site nodule 7.2% (placebo 3.4%)
weight increased 7.2% (placebo 3.4%)
injection site pain 6.7% (placebo 6.1%)
NCT03503318 · Phase 3 · monotherapy
q1m
injection site pain 5.2%
injection site nodule 1.7%
NCT03893825 · Phase 3 · monotherapy
q2m
injection site nodule 5.6%
injection site pain 4.3%
NCT03893825 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Risperidone (Uzedy)

Relapse 7.1% (n=183) vs 29.3% (n=181) placeboq1m
event count · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
show 7 more results
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
13.3% (n=180) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
0.07% (n=183) vs 0.28% (n=181) placebo @ 24wkq1m
NCT03503318 · Phase 3 · monotherapy
0.11% (n=179) vs 0.28% (n=181) placebo @ 24wkq2m
NCT03503318 · Phase 3 · monotherapy
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
Clinical Remission 21.3% (n=183) vs 16.6% (n=181) placeboq1m
responder rate · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 39 Participants as posted
show 1 more result
23.5% (n=179) vs 16.6% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
Relapse 100% (n=1)q2m
event count · % of participants
No placebo or comparator arm
NCT03503318 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
SQLS -4.5 vs 0.9 placebo scoreq1m
absolute change · score
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-4.1 vs 0.9 placebo scoreq2m
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
CDSS -0.3 vs -0.4 placebo scoreq1m
absolute change · score
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-0.8 vs -0.4 placebo scoreq2m
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Uzedy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Risperidone (Uzedy): no structured comparison results are available for Bipolar Disorder.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Uzedy)'s landscape